Applied DNA Sciences, Inc. (APDN)
NASDAQ: APDN · IEX Real-Time Price · USD
1.880
-0.070 (-3.59%)
At close: May 21, 2024, 2:13 PM
1.890
+0.010 (0.53%)
After-hours: May 21, 2024, 6:58 PM EDT
Applied DNA Sciences Revenue
Applied DNA Sciences had revenue of $5.52M in the twelve months ending March 31, 2024, down -68.52% year-over-year. Revenue in the quarter ending March 31, 2024 was $929.63K, a -78.91% decrease year-over-year. In the fiscal year ending September 30, 2023, Applied DNA Sciences had annual revenue of $13.37M, a decrease of -26.43%.
Revenue (ttm)
$5.52M
Revenue Growth
-68.52%
P/S Ratio
0.33
Revenue / Employee
$106,113
Employees
52
Market Cap
1.85M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 13.37M | -4.80M | -26.43% |
Sep 30, 2022 | 18.17M | 9.14M | 101.25% |
Sep 30, 2021 | 9.03M | 7.10M | 367.40% |
Sep 30, 2020 | 1.93M | -3.46M | -64.16% |
Sep 30, 2019 | 5.39M | 1.49M | 38.06% |
Sep 30, 2018 | 3.90M | -847.92K | -17.85% |
Sep 30, 2017 | 4.75M | 564.83K | 13.49% |
Sep 30, 2016 | 4.19M | -4.82M | -53.53% |
Sep 30, 2015 | 9.01M | 6.29M | 231.05% |
Sep 30, 2014 | 2.72M | 685.00K | 33.64% |
Sep 30, 2013 | 2.04M | 181.53K | 9.79% |
Sep 30, 2012 | 1.85M | 885.85K | 91.43% |
Sep 30, 2011 | 968.85K | 449.00K | 86.37% |
Sep 30, 2010 | 519.84K | 224.68K | 76.12% |
Sep 30, 2009 | 295.16K | -577.85K | -66.19% |
Sep 30, 2008 | 873.01K | 751.09K | 616.05% |
Sep 30, 2007 | 121.92K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Dynatronics | 33.60M |
iSpecimen | 9.27M |
SCWorx | 3.92M |
60 Degrees Pharmaceuticals | 569.86K |
Aclarion | 60.05K |
APDN News
- 8 days ago - Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML - Accesswire
- 11 days ago - Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results - Accesswire
- 11 days ago - Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement - Accesswire
- 26 days ago - Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program - Accesswire
- 4 weeks ago - Applied DNA Announces 1-For-20 Reverse Stock Split - Accesswire
- 2 months ago - Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start - Accesswire
- 2 months ago - Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress - Accesswire
- 3 months ago - Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results - Accesswire